Skip to main content
. 2022 May 17;12:178. doi: 10.1038/s41398-022-01943-9

Fig. 6. Intra-mPFC infusion of IGF-1 nAb at 2 h post-ketamine blocks the antidepressant-like effects of ketamine in LPS-induced depression model mice: involvement of mTORC1 signaling in the antidepressant-like actions of IGF-1.

Fig. 6

a Experimental timeline for LPS challenge (0.8 mg/kg, i.p.), i.p. injection of either saline or ketamine (10 mg/kg), intra-mPFC infusion of either control IgG (160 ng/side) or IGF-1 nAb (160 ng/side), and behavioral testing. b Locomotor activity (LMA) 24 h after LPS challenge (F3,18 = 1.92, p = 0.163, n = 5–6). b Immobility time in the tail suspension test (TST) 26 h after LPS challenge (F3,18 = 9.43, p = 0.0006, n = 5–6). c Immobility time in the forced swim test (FST) 28 h after LPS challenge (F3,18 = 7.45, p = 0.0019, n = 5–6). e Schematic representation of mPFC infusion sites. Plates are from ref. [50]; 1.94, 1.78, 1.70, and 1.54 indicate distances (mm) from bregma. f Experimental timeline for LPS challenge, intra-mPFC infusion of vehicle (10% DMSO/0.09% BSA/PBS), IGF-1 (50 ng/side) or IGF-1 plus rapamycin (0.01 nmol/side), and behavioral testing. g LMA 24 h after LPS challenge (F2,17 = 1.55, p = 0.242, n = 6–7). h Immobility time in the TST 26 h after LPS challenge (F2,17 = 14.9, p = 0.0002, n = 6–7). i Immobility time in the FST 28 h after LPS challenge (F2,17 = 11.6, p = 0.0007, n = 6–7). j Schematic representation of mPFC infusion sites. Plates are from ref. [50]; 1.94, 1.78, 1.70, and 1.54 indicate distances (mm) from bregma. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01 (one-way ANOVA followed by Tukey’s post hoc test).